Dr. Reddy's Laboratories vs Smith & Nephew

Dr. Reddy's Laboratories (RDY), health care, and Smith & Nephew (SNN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Smith & Nephew is worth $12.8B on the stock market and Dr. Reddy's Laboratories $12.3B: Smith & Nephew is valued at 3% more. Dr. Reddy's Laboratories trades at 41.1 times earnings and Smith & Nephew at 20.8; operating margins in their latest fiscal years were 15.0% and 12.9%. Over the past year Dr. Reddy's Laboratories's share price has moved +4.85% and Smith & Nephew's -4.82%.

Key facts

Dr. Reddy's Laboratories market value
$12.3B
Smith & Nephew market value
$12.8B
Dr. Reddy's Laboratories P/E
41.1
Smith & Nephew P/E
20.8
Dr. Reddy's Laboratories revenue
$3.6BFY to 2026-03-31
Smith & Nephew revenue
$6.2BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Dr. Reddy's Laboratories vs Smith & Nephew: every measure side by side
Measure Dr. Reddy's Laboratories Smith & Nephew
SectorHealth CareHealth Care
Country India United Kingdom
Fiscal year ends2026-03-312025-12-31
Size
Market cap$12.3Blower$12.8Bhigher
Revenue$3.6Blower$6.2Bhigher
Earnings$456Mlower$625Mhigher
Employees27,527higher17,000lower
Total assets$6.2Blower$10.5Bhigher
Valuation
P/E41.1higher20.8lower
P/S3.4higher2.1lower
P/B——
Dividend yield——
Profitability
Operating margin15.0%higher12.9%lower
Balance sheet
Net assets$4Blower$5.3Bhigher
Total liabilities$2.1Blower$5.2Bhigher
Total debt$193.7Mlower$3.1Bhigher
Cash on hand$163.5Mlower$557Mhigher
Price change
Today+0.61%higher-1.49%lower
1 year+4.85%higher-4.82%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Dr. Reddy's Laboratories only (0)

None of the tracked investors.

Smith & Nephew only (2)

Percentages are each holding's share of that investor's reported portfolio. Who owns RDY · Who owns SNN

Further comparisons

Learn

Questions and answers

Which is bigger, Dr. Reddy's Laboratories or Smith & Nephew?

By market value, Smith & Nephew is the larger: $12.8B against $12.3B for Dr. Reddy's Laboratories. By revenue in its latest fiscal year, Smith & Nephew is the larger: $6.2B against $3.6B for Dr. Reddy's Laboratories.

Which has the higher P/E ratio?

Dr. Reddy's Laboratories: 41.1, against 20.8 for Smith & Nephew. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Dr. Reddy's Laboratories: 15.0%, against 12.9% for Smith & Nephew. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Smith & Nephew: $3.1B, against $193.7M for Dr. Reddy's Laboratories. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Dr. Reddy's Laboratories and Smith & Nephew?

None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Dr. Reddy's Laboratories and 2 hold Smith & Nephew.

Cite this page

Funkfolio, “Dr. Reddy's Laboratories vs Smith & Nephew”, data as of 18 November 2026. https://funkfolio.com/compare/rdy-vs-snn

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.